Literature DB >> 14623007

Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action.

Christian Hubschwerlen1, Jean-Luc Specklin, Daniel K Baeschlin, Yves Borer, Sascha Haefeli, Christine Sigwalt, Susanne Schroeder, Hans H Locher.   

Abstract

Oxazolidinone-quinolone hybrids, which combine the pharmacophores of a quinolone and an oxazolidinone, were synthesised and shown to be active against a variety of susceptible and resistant Gram-positive and Gram-negative bacteria. The nature of the spacer greatly influences the antibacterial activity by directing the mode of action, that is quinolone- and/or oxazolidinone-like activity. The best compounds in this series have a balanced dual mode of action and overcome all types of resistance, including resistance to quinolones and linezolid, in clinically relevant Gram-positive pathogens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14623007     DOI: 10.1016/j.bmcl.2003.07.028

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  10 in total

Review 1.  Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents.

Authors:  Julian Gregston Hurdle; Alexander John O'Neill; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

2.  MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile.

Authors:  Michelle M Butler; Dean L Shinabarger; Diane M Citron; Ciarán P Kelly; Sofya Dvoskin; George E Wright; Hanping Feng; Saul Tzipori; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

3.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

Review 4.  Strategies to potentiate antimicrobial photoinactivation by overcoming resistant phenotypes.

Authors:  Domingo Mariano Adolfo Vera; Mark H Haynes; Anthony R Ball; Tianhong Dai; Christos Astrakas; Michael J Kelso; Michael R Hamblin; George P Tegos
Journal:  Photochem Photobiol       Date:  2012-02-13       Impact factor: 3.421

Review 5.  Comprehensive review of chemical strategies for the preparation of new aminoglycosides and their biological activities.

Authors:  Nishad Thamban Chandrika; Sylvie Garneau-Tsodikova
Journal:  Chem Soc Rev       Date:  2018-02-19       Impact factor: 54.564

6.  Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound.

Authors:  Michelle M Butler; William A Lamarr; Kimberly A Foster; Marjorie H Barnes; Donna J Skow; Patrick T Lyden; Lauren M Kustigian; Chengxin Zhi; Neal C Brown; George E Wright; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

7.  In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.

Authors:  Gregory T Robertson; Eric J Bonventre; Timothy B Doyle; Qun Du; Leonard Duncan; Timothy W Morris; Eric D Roche; Dalai Yan; A Simon Lynch
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

8.  Synthesis and evaluation of hetero- and homodimers of ribosome-targeting antibiotics: antimicrobial activity, in vitro inhibition of translation, and drug resistance.

Authors:  Yifat Berkov-Zrihen; Keith D Green; Kristin J Labby; Mark Feldman; Sylvie Garneau-Tsodikova; Micha Fridman
Journal:  J Med Chem       Date:  2013-07-01       Impact factor: 7.446

Review 9.  The future of antibiotics begins with discovering new combinations.

Authors:  Meilin Zhu; Megan W Tse; Juliane Weller; Julie Chen; Paul C Blainey
Journal:  Ann N Y Acad Sci       Date:  2021-07-02       Impact factor: 6.499

Review 10.  Architecture and conservation of the bacterial DNA replication machinery, an underexploited drug target.

Authors:  Andrew Robinson; Rebecca J Causer; Nicholas E Dixon
Journal:  Curr Drug Targets       Date:  2012-03       Impact factor: 3.465

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.